The FDA has revised the warning labels on Johnson & Johnson’s Invokana and AstraZeneca’s Farxiga to include information about acute kidney injury and how to minimize risk for it.
According to the FDA, between March 2013 and October 2015, the agency received reports of 101 confirmed cases of acute kidney injury, some of which required hospitalization and dialysis, related to Invokana/Invokamet and Farxiga/Xigduo XR.
Jardiance, offered by Eli Lilly and Boehringer Ingelheim, is now the only med in the SGLT2 class of diabetes drugs not carrying a kidney warning.
Read the Helio coverage